1. Generics Bulletin
  2. >>Products
  3. >>Generics

Generic Drug Cluster: What Are Global Regulators Discussing?

FDA’s Sarah Ibrahim Outlined Key Generic Drug Topics Among Seven Health Agencies

 
• By Urtė Fultinavičiūtė

In its ongoing attempt to embrace international harmonization, the US Food and Drug Administration invited stakeholders from both sides of the Atlantic to discuss how global health regulators can join forces to improve generic drug development at a recent webinar on “Expanding Generic Drug Access Through International Engagements.”

Illustration of officials at a roundtable and world map in the background
The Generic Drug Cluster has seven regulatory bodies • Source: Shutterstock

“Recognizing the interconnectedness of actions across countries, collaboration emerges as essential,” said Sarah Ibrahim, associate director for global affairs at the Office of Generic Drugs at the US Food and Drug Administration, during her introductory session on OGD’s global affairs and international engagement at a recent webinar on “Expanding Generic Drug Access Through International Engagements.”.

Ibrahim noted how harmonization and alignment of regulatory standards and requirements across global regions play a “crucial role in fostering...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

Welch Heads Up Par Ahead Of Planned Spin-Off After Endo-Mallinckrodt Merger

 
• By Dave Wallace

As Endo and Mallinckrodt continue to work towards consummating the merger they announced earlier this year, the pair have revealed further organizational details of their combined generics and sterile injectables business, which is set to be spun off after the merger is complete.

Generic Drug Office’s Policy Staff Returning To US FDA

 
• By Derrick Gingery

The group had been laid off as part of the 1 April reduction-in-force, which lead to missed guidance publication deadlines.

Stelara Biosimilar Sees Stada’s Specialty Sales Start Strong In Q1

 
• By Dave Wallace

Stada’s Specialty division was boosted by the firm’s launch last year of a European Stelara biosimilar, even as generics growth remained muted in Q1.

Lupin Concedes To Wakix IP With 2030 Launch Date Agreement

 
• By Dean Rudge

Ahead of a bench trial beginning in February 2026, Lupin has become the latest ANDA sponsor to settle patent-infringement litigation over Harmony Biosciences’ Wakix (pitolisant hydrochloride), which has been touted as a potential blockbuster by the end of the decade.

More from Products